– OASIS-HAE is the registrational study in Ionis’ donidalorsen Phase 3 clinical program and further expands Ionis’ late-stage pipeline – Donidalorsen is one of Ionis’ wholly owned medicines the company plans to commercialize CARLSBAD, Calif. , Nov. 18, 2021 /PRNewswire/ — Ionis Pharmaceuticals,

– New data to be presented from multiple ascending dose study for Ionis’ novel antisense medicine targeting PCSK9 – Data on the effect of olezarsen on a variety of lipoprotein fractions in patients with hypertriglyceridemia to be presented – Ionis to host symposium on lessening the disproportionate

CARLSBAD, Calif. , Nov. 9, 2021 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following virtual investor conferences:     Stifel 2021 Healthcare Conference on Monday, November 15, 2021 Evercore ISI 4 th

– Positive Phase 2 study results demonstrate significant efficacy of donidalorsen (formerly IONIS-PKK-LRx) in the reduction of hereditary angioedema attacks – Based on the results of the Phase 2 study, Ionis plans to initiate a Phase 3 program of donidalorsen in people with HAE CARLSBAD, Calif.

Olezarsen (IONIS-APOCIII-L Rx) Phase 3 CORE study in patients with sHTG initiated Donidalorsen (IONIS-PKK-L Rx) Phase 2 data to be presented at ACAAI Annual Meeting; Phase 3 initiation on track for year-end Tofersen Phase 3 VALOR study missed primary endpoint; signs of reduced disease progression